Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Diabetic Retinopathy Market from 2024 to 2025?
The market for diabetic retinopathy has expansively surged in recent periods. Its growth is projected to go up from $8.61 billion in 2024 to $9.29 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.9%. This growth within the historic period is linked to factors such as an aging demographic, a rise in diabetes cases, greater consciousness about diabetic retinopathy, enhanced health infrastructure, and increased spending on healthcare services.
What Is the Projected Market Size of the Diabetic Retinopathy Market?
In the coming years, the market size for diabetic retinopathy is projected to experience significant expansion. It is expected to reach $12.56 billion in 2029 with a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth in the predicted period include personalized medical treatments, the growth of telemedicine services, advancements in therapeutic interventions, incorporation of point-of-care testing and remote patient monitoring. Foreseeable trends in the forecast period encompass precision medicine in treating diabetic retinopathy, improving focus on early detection and prevention, growth of teleophthalmology services, increasing gene therapy research, and ongoing improvements in retinal imaging technology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12187&type=smp
Who are the Major Competitors in the Diabetic Retinopathy Market Outlook?
Major companies operating in the diabetic retinopathy market include Pfizer Inc., F-Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Oxurion NV, Graybug Vision Inc., Ampio Pharmaceuticals Inc.
What Is Fueling Growth in the Diabetic Retinopathy Market?
The diabetic retinopathy market is set to expand on the back of an increasing prevalence of diabetes. This long-lasting metabolic disease, associated with high blood glucose levels, is primarily caused by reasons such as excess weight, obesity, genetic predisposition, and lack of physical activity. Excessive blood sugar in diabetes patients has the potential to harm the retina, which plays a crucial role in detecting light and transmitting signals to the brain through a nerve at the back of the eye. As per a report by the Office for Health Improvement and Disparities, a UK based government body, in March 2024, between March 2022 and March 2023, there was a 22% increase in the percentage of individuals with type 1 diabetes receiving all the eight advised care processes. Similarly, for type 2 diabetes, this increment was 21%. Moreover, the percentage of individuals attaining target HbA1c levels touched 37.9%, the highest figure ever noted by the National Diabetes Audit. Hence, the escalating prevalence of diabetes is stimulating the growth of the diabetic retinopathy market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12187&type=smp
Which Diabetic Retinopathy Market Segments Are Growing the Fastest?
The diabetic retinopathy market covered in this report is segmented –
1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery
3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization, Vitreous Hemorrhage, Tractional Retinal Detachment
2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR, Moderate NPDR, Severe NPDR
Which Industry Trends Are Shaping the Future of the Diabetic Retinopathy Market?
In the arena of diabetic retinopathy, technological advancements are becoming increasingly trendy. Major firms in the large volume parenteral market are embracing cutting-edge technology to maintain their market stance. For instance, Baxter International Inc., a healthcare firm based in the U.S., launched the Welch Allyn RetinaVue 100 Imager PRO in South Korea in July 2022. This technology is designed to facilitate the detection of diabetic retinopathy in primary care environments. RetinaVue has shown to enhance patient compliance for annual diabetic retinal exams (DREs) which can be life-saving, by enabling swift and comfortable screenings during routine primary care visits.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report
Which Countries Are Leading the Diabetic Retinopathy Market?
North America was the largest region in the diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12187
This Report Delivers Insight On:
1. How big is the diabetic retinopathy market, and how is it changing globally?
2. Who are the major companies in the diabetic retinopathy market, and how are they performing?
3. What are the key opportunities and risks in the diabetic retinopathy market right now?
4. Which products or customer segments are growing the most in the diabetic retinopathy market?
5. What factors are helping or slowing down the growth of the diabetic retinopathy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
